CODX - コ・ダイアグノスティックス （Co-Diagnostics Inc.） コ・ダイアグノスティックスCODXのチャート
CODXの企業情報
| symbol | CODx |
|---|---|
| 会社名 | Co-Diagnostics Inc （コ・ダイアグノスティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Co-Diagnostics Inc. is a molecular diagnostics company. The Company is engaged in developing manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis a drug resistant tuberculosis test hepatitis B and C Malaria dengue human immunodeficiency virus and Zika virus all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. コ・ダイアグノスティックスは米国の医療関連企業。主に、医療診断における試薬の開発・製造・販売に従事する。核酸分子の検出および分析の診断テストに使用される試薬を開発、完結型ラボ・システムを販売する。また、病気や遺伝的疾患の治療のため、DNAベ―スの試験プラットフォ―ムを開発する。本社所在地はユタ州ソルト・レ―ク・シティ―。 |
| 本社所在地 | 2401 S. Foothill Drive Suite D Salt Lake City UT 84109 USA |
| 代表者氏名 | Dwight H. Egan ドワイト・エガン |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 801-278-9769 |
| 設立年月日 | 41365 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2017年 |
| 従業員数 | 15人 |
| url | www.codiagnostics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/codx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -5.87956 |
| 終値（lastsale） | 2.3054 |
| 時価総額（marketcap） | 28467141.4458 |
| 時価総額 | 時価総額（百万ドル） 27.78306 |
| 売上高 | 売上高（百万ドル） 0.02460 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 26.25479 |
| 当期純利益 | 当期純利益（百万ドル） -8.08090 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Co-Diagnostics Inc revenues increased from $2K to $19K. Net loss increased 72% to $2.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 46% to $655K (expense) Sales and marketing increase of 26% to $239K (expense). |
CODXのテクニカル分析
CODXのニュース
Insider Selling: Co-Diagnostics, Inc. (NASDAQ:CODX) CEO Sells 38,046 Shares of Stock 2021/01/21 11:47:20 Watchlist News
Co-Diagnostics, Inc. (NASDAQ:CODX) CEO Dwight H. Egan sold 38,046 shares of the firm’s stock in a transaction dated Friday, January 15th. The shares were sold at an average price of $11.00, for a total transaction of $418,506.00. Following the transaction, the chief executive officer now directly owns 50,000 shares in the company, valued at approximately […]
Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference 2021/01/07 14:30:00 Benzinga
SALT LAKE CITY , Jan. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX ) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion on diagnostics and devices hosted by Scott Gottlieb , M.D., at the H.C. Wainwright & Co. BioConnect 2021 Conference, being held January 11-14 . Dr. Gottlieb is the former Food and Drug Administration (FDA) Commissioner and former … Full story available on Benzinga.com
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products 2021/01/06 14:30:00 PR Newswire
SALT LAKE CITY, Jan. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial…
Concerns linger after Iowa spends $230K on contact tracing software 2021/01/04 16:55:51 The Gazette Iowa
Iowa has paid more than $230,000 so far to a Utah company for contact tracing software that still is causing delays for some public health departments as they track COVID-19. In a service order amendment signed in July by Paul Trombino, interim director of the Iowa Department of Administrative Services , the state agreed to pay Domo $75,000 a year for a new custom app for COVID-19 case investigation and contact tracing. That subscription fee was prorated to $55,479 for the first year of a three-year contract, which The Gazette obtained through an open records request. The deal also calls for Iowa to pay $175,000 for professional services for app implementation. Several local public health departments were critical of the software in November , saying it was slowing their contact tracing at a time the virus was surging. Since then, the state has started holding weekly webinars to answer public health officials’ questions, but delays continue. “There are still some slower days, where the system seems to lag with data input,” Sam Jarvis, community health division manager for the Johnson County Department of Public Health, said in late December.
Co-Diagnostics, Inc. (NASDAQ:CODX) Director Eugene Durenard Sells 10,000 Shares of Stock 2020/12/15 10:06:43 Watchlist News
Co-Diagnostics, Inc. (NASDAQ:CODX) Director Eugene Durenard sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 10th. The stock was sold at an average price of $10.15, for a total transaction of $101,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. […]
Insider Selling: Co-Diagnostics, Inc. (NASDAQ:CODX) CEO Sells 38,046 Shares of Stock 2021/01/21 11:47:20 Watchlist News
Co-Diagnostics, Inc. (NASDAQ:CODX) CEO Dwight H. Egan sold 38,046 shares of the firm’s stock in a transaction dated Friday, January 15th. The shares were sold at an average price of $11.00, for a total transaction of $418,506.00. Following the transaction, the chief executive officer now directly owns 50,000 shares in the company, valued at approximately […]
Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference 2021/01/07 14:30:00 Benzinga
SALT LAKE CITY , Jan. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX ) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion on diagnostics and devices hosted by Scott Gottlieb , M.D., at the H.C. Wainwright & Co. BioConnect 2021 Conference, being held January 11-14 . Dr. Gottlieb is the former Food and Drug Administration (FDA) Commissioner and former … Full story available on Benzinga.com
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products 2021/01/06 14:30:00 PR Newswire
SALT LAKE CITY, Jan. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial…
Concerns linger after Iowa spends $230K on contact tracing software 2021/01/04 16:55:51 The Gazette Iowa
Iowa has paid more than $230,000 so far to a Utah company for contact tracing software that still is causing delays for some public health departments as they track COVID-19. In a service order amendment signed in July by Paul Trombino, interim director of the Iowa Department of Administrative Services , the state agreed to pay Domo $75,000 a year for a new custom app for COVID-19 case investigation and contact tracing. That subscription fee was prorated to $55,479 for the first year of a three-year contract, which The Gazette obtained through an open records request. The deal also calls for Iowa to pay $175,000 for professional services for app implementation. Several local public health departments were critical of the software in November , saying it was slowing their contact tracing at a time the virus was surging. Since then, the state has started holding weekly webinars to answer public health officials’ questions, but delays continue. “There are still some slower days, where the system seems to lag with data input,” Sam Jarvis, community health division manager for the Johnson County Department of Public Health, said in late December.
Co-Diagnostics, Inc. (NASDAQ:CODX) Director Eugene Durenard Sells 10,000 Shares of Stock 2020/12/15 10:06:43 Watchlist News
Co-Diagnostics, Inc. (NASDAQ:CODX) Director Eugene Durenard sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 10th. The stock was sold at an average price of $10.15, for a total transaction of $101,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. […]
Insider Selling: Co-Diagnostics, Inc. (NASDAQ:CODX) CEO Sells 38,046 Shares of Stock 2021/01/21 11:47:20 Watchlist News
Co-Diagnostics, Inc. (NASDAQ:CODX) CEO Dwight H. Egan sold 38,046 shares of the firm’s stock in a transaction dated Friday, January 15th. The shares were sold at an average price of $11.00, for a total transaction of $418,506.00. Following the transaction, the chief executive officer now directly owns 50,000 shares in the company, valued at approximately […]
Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference 2021/01/07 14:30:00 Benzinga
SALT LAKE CITY , Jan. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX ) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion on diagnostics and devices hosted by Scott Gottlieb , M.D., at the H.C. Wainwright & Co. BioConnect 2021 Conference, being held January 11-14 . Dr. Gottlieb is the former Food and Drug Administration (FDA) Commissioner and former … Full story available on Benzinga.com
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products 2021/01/06 14:30:00 PR Newswire
SALT LAKE CITY, Jan. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial…
Concerns linger after Iowa spends $230K on contact tracing software 2021/01/04 16:55:51 The Gazette Iowa
Iowa has paid more than $230,000 so far to a Utah company for contact tracing software that still is causing delays for some public health departments as they track COVID-19. In a service order amendment signed in July by Paul Trombino, interim director of the Iowa Department of Administrative Services , the state agreed to pay Domo $75,000 a year for a new custom app for COVID-19 case investigation and contact tracing. That subscription fee was prorated to $55,479 for the first year of a three-year contract, which The Gazette obtained through an open records request. The deal also calls for Iowa to pay $175,000 for professional services for app implementation. Several local public health departments were critical of the software in November , saying it was slowing their contact tracing at a time the virus was surging. Since then, the state has started holding weekly webinars to answer public health officials’ questions, but delays continue. “There are still some slower days, where the system seems to lag with data input,” Sam Jarvis, community health division manager for the Johnson County Department of Public Health, said in late December.
Co-Diagnostics, Inc. (NASDAQ:CODX) Director Eugene Durenard Sells 10,000 Shares of Stock 2020/12/15 10:06:43 Watchlist News
Co-Diagnostics, Inc. (NASDAQ:CODX) Director Eugene Durenard sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 10th. The stock was sold at an average price of $10.15, for a total transaction of $101,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. […]